NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT02784171 2024-12-10Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCanadian Cancer Trials GroupPhase 2/3 Completed520 enrolled 16 charts 1 FDA